GO with 7 + 3 has shown statistically significant survival advantage in patients with FLT3 mutant AML (NCT03900949), providing another avenue of opportunity for studies examining this regimen in combination with FLT3-inhibitors [13]. Here, FLT3 is linked to acute myeloid leukemia.